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In  this  mini-review  we  brieﬂy  describe  some  historical  developments  made  in the  ﬁeld  of enzymatic  fuel
cells (FCs),  discussing  important  design  considerations  taken  when  constructing  mediator-,  cofactor-,
and  membrane-less  biological  FCs  (BFCs).  Since  the  topic  is  rather  extensive,  only  BFCs  utilizing  direct
electron  transfer  (DET)  reactions  on both  the anodic  and  cathodic  sides  are  considered.  Moreover,  theeywords:
nzymatic fuel cells
irect electron transfer
mplantable biodevices
x vivo situations
mart electronic contact lenses
performance  of mostly  glucose/oxygen  biodevices  is  analyzed  and  compared.  We  also  present  some
unpublished  results  on  mediator-,  cofactor-,  and  membrane-less  glucose/oxygen  BFCs  recently  designed
in our  group  and  tested  in  different  human  physiological  ﬂuids,  such  as blood,  plasma,  saliva,  and  tears.
Finally,  further  perspectives  for BFC  applications  are  highlighted.
© 2012 Elsevier Ltd. Open access under CC BY-NC-ND license.. Introduction
Biofuel cells (BFCs) constitute a subset of fuel cells (FCs) that
mploy biocatalysts instead of the typical non-biogenous catalysts.
he biocatalyst can be a microorganism, as in microbial BFCs, which
se whole living cells to extract power from different fuels and
xidants, or an enzyme, as in enzymatic BFCs, which instead use
edox enzymes directly [1].
The very ﬁrst BFC was conceived in the early 20th century,
hen M.C. Potter used microbial cells on platinum electrodes to
roduce electricity [2]. Clark and Lyons coined the term “enzyme
lectrode” in the early 1960s, using glucose oxidase (GOx) to oxi-
ize glucose in close proximity to a Clark electrode [3]. A couple
f years later this work was followed by the ﬁrst report on an
nzymatic FC, where GOx was used to create a bioanode [4]. Since
Abbreviations: ADH, alcohol dehydrogenase; AOx, ascorbate oxidase; AuNP, gold
anoparticle; BFC, biofuel cell; BMCO, blue multi-copper oxidase; BOx, bilirubin oxi-
ase; CDH, cellobiose dehydrogenase; CNT, carbon nanutube; Cp, ceruloplasmin;
yt c, cytochrome; c DET, direct electron transfer; EtOH, ethanol; FAD, ﬂavin; FC,
uel  cell; FDH, fructose dehydrogenase; GA, glutaraldehyde; NP, nanoparticle; GOx,
lucose oxidase; H2O2, hydrogen peroxide; Hd, hydrogenase; HRP, horseradish per-
xidase; KB, Ketjen black; Lc, laccase; MBH, membrane-bound hydrogenase; MET,
ediated electron transfer; MP,  microperoxidase; MWCNT, multi-walled carbon
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Open access under CC BY-NC-ND license.then, many improvements have been made and enzymatic FCs
have received increasingly more attention following the discov-
ery of new redox enzymes. Further, new electrode materials were
developed, and rational ways to electrically interconnect enzymes
and electrodes were established. Several reviews published the last
years cover the latest developments and the different challenges
that the BFC ﬁeld is facing, with noteworthy publications in Chem-
ical Reviews made by Atanassov et al., Armstrong et al., and Heller
[1,5–9].
In an enzymatic FC, either one or both electrodes, i.e. the
bioanode and/or the biocathode, utilize enzymes to bioelectrocat-
alytically oxidize the fuel and to reduce the oxidant. A wide range of
fuels and oxidants can be used to extract electrical power; the par-
ticular fuel will be dependant on the enzyme used. The biofuel, e.g.
carbohydrates, alcohols, or even amino acids, is oxidized by an oxi-
doreductase, transferring electrons from the fuel to the bioanode.
Electrons are then released at the biocathode, where the biooxidant,
e.g. molecular oxygen (O2), hydrogen peroxide (H2O2), or organic
peroxides (ROOR′), is reduced by another oxidoreductase.
Enzymes are attractive to use as FC electron shuttles due
to their high substrate speciﬁcity, i.e.  being very selective in
terms of the fuel or oxidant that is oxidized or reduced,
making half cell separation, i.e. usage of membranes, unneces-
sary. Also, enzyme production is relatively inexpensive, enabling
their use in non-generic applications. The ability of enzymes
to utilize biologically derived fuels, such as e.g. glucose, fruc-
tose, lactose, ascorbate, dopamine, and alcohols, along with
ubiquitous O2 as the biooxidant, makes the use of enzyme
based BFCs very attractive for an array of applications, espe-
cially as electric power sources in implantable devices in
living organisms. The enzymes themselves, as well as their
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eaction products, can also be considered as relatively safe com-
ared to non-biogenous catalysts; an important consideration
ndeed, in an implantable situation.
Depending on how the electric connection between a par-
icular electrode/enzyme pair is realized, enzymatic FCs can be
ivided into two main groups: (i) mediated electron transfer (MET)
evices, in which redox species either in solution or as immobilized
edox polymers are used to channel the electrons to (and from)
he electrode surface, and (ii) direct electron transfer (DET) based
iodevices, where the enzyme is able to communicate directly
ith the electrode. The electron transfer between enzymes and
lectrodes using different pathways has been reviewed in detail
reviously (e.g. [10]).
Over 1400 oxidoreductases are known to date (www.enzyme-
atabase.org), any of which could possibly be utilized as
ioelements in an enzymatic FC. In the majority of cases, the use
f mediators is needed to electrically connect the enzyme to the
lectrode, since less than about a hundred of the known oxidore-
uctases are capable to communicate with an electrode surface via
 DET mechanism [11]. Many redox enzymes have their catalytic
ites buried deeply within the protein matrix, which acts to insulate
he redox site and will eventually prevent DET.
In spite of the difﬁculties in achieving DET, it possesses some
mportant advantages over MET. Mediators are often health haz-
rds and their usage leads to voltage losses arising from the
otential difference between the active site of the enzyme and
he mediator. Employing a DET based design allows for signiﬁcant
impliﬁcations in the construction of BFCs, since no membranes
r compartments are necessary, making miniaturization easier. Of
ll the enzymes that have been successfully connected directly to
lectrodes so far, most contain an active site that is either rela-
ively exposed at the surface of the protein, where the maximal
ractical distance is limited by the distance an electron can tun-
el given the particular circumstances (i.e. about 1.5 nm [12]), or
uried in the protein matrix but connected to the surface by a set
Fig. 1. Principal scheme of a single compartment mediator- ancta 82 (2012) 191– 202
of cofactors. Indeed, in 1991 Guo and Hill grouped all oxidoreduc-
tases into intrinsic or extrinsic enzymes, based on structure–DET
relationships [13]. One of the main downsides of using the DET
approach to construct BFCs is the difﬁculty to electrically connect
sufﬁcient amounts of the enzyme. Limited by the active surface
area, the efﬁciency and the power output of DET biodevices will
thus be attenuated.
As early as in 1972 the ﬁrst report concerning DET reactions
between native horse-heart cytochrome c (cyt c) and different elec-
trodes, such as Hg, Pt, and Au, was published [14]. In spite of this
fact, most scientists cite Kuwana’s and Hill’s papers as the ﬁrst
reports on successful DET reactions between the protein and solid
electrodes [15,16]. Since cyt c has no intrinsic enzymatic activity
the ﬁrst reports about unambiguous DET based enzymatic bioelec-
trocatalysis appeared a few years later, when laccase (Lc) directly
adsorbed on graphite electrodes was investigated potentiometri-
cally and voltamperometrically [17,18]. However, the very ﬁrst BFC,
where both the anodic and the cathodic bioelements were in DET
contact with electrodes, was reported almost a quarter of a century
later, when Tarasevich and co-workers published a letter to the
Editor of Russian Journal of Electrochemistry entitled: “Composite
materials for direct bioelectrocatalysis of the hydrogen and oxy-
gen reactions in biofuel cells” [19]. Due to the absence of detailed
information concerning the fabrication and characterization of bio-
electrodes and possibly some other reasons, this paper is not cited
by the scientiﬁc community, notwithstanding the impressive char-
acteristics of the H2/O2 BFC presented, even when compared to
current BFC developments: an operating voltage of 0.8 V at a current
density of 400 A cm−2 (cf. H2/O2 biodevices in Table 1).
Generally speaking, DET based BFCs present an attractive design
for potentially implantable purposes due to the simplicity of fab-
rication, the possibility of miniaturization, non-toxicity, excluding
the need to use membranes and compartments, etc.  A principal
scheme of a compartment-, mediator-, and cofactor-less BFC is
shown in Fig. 1. In the rest of this article we chose to focus on
d cofactor-less direct electron transfer based biofuel cell.
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Table 1
Comparison of direct electron transfer based biofuel cells.
Fuel/oxidant Bioelements (anode/cathode) Solution OCV (V) Power (W cm−2) Stability (h) Refs.
H2/O2 Hd/Lc Citrate-PB pH 8.0
anolyte, pH 4.2
catholyte
1.35a 400 >168 Tarasevich et al. [19]
H2/O2 MBH/Lc Acetate buffer pH 6,
10 mM glucose and
EtOH
0.97 7 >0.25 Vincent et al. [95]
EtOH/H2O2 ADH/MP-11 Citrate buffer pH 5,
bubbling of H2 and air
0.27 0.2 ∼60 Ramanavicius et al. [71]
Fructose/O2 FDH/Lc McIlvaine buffer pH 5,
200 mM fructose and
O2 sat.
0.79 840 >12 Kamitaka et al. [81]
Fructose/O2 FDH/Lc Citrate buffer pH 5,
200 mM fructose and
bubbling of air
0.66 126 ∼87 Wu  et al. [84]
Glucose/O2 CDH/Lc Citrate buffer pH 4.5,
5  mM glucose
0.73 >5 ∼25 Coman et al. [65]
Glucose/O2 CDH/BOx PBS pH 7.4, 5 mM
glucose
0.62 3 >6 Coman et al. [64]
Serum 0.58 4 <2
Glucose/O2 GOx/Lc PBS pH 7.4, 5 mM
glucose
0.23 30 n.d. Pan et al. [83]
Blood 0.12 5.6 n.d.
Glucose/O2 GOx/Lc PB pH 7, 50 mM glucose 0.95 1300 ∼2.7b Zebda et al. [85]
Glucose/O2 CDH/BOx PBS pH 7.4, 5 mM
glucose
0.66 3.2 ∼30 Wang et al. [66]
Blood 0.66 2.8 ∼2
Plasma 0.63 3 ∼8
Saliva 0.63 2.1 ∼1c d
Glucose/O2 CDH/BOx Tears 0.57 3.5 >10 Falk et al. [105]
n.d., not determined.
a OCV higher than 1.23 V was obtained due to catholyte/anolyte pH difference.
b Half-life was  recalculated from OCV drop.
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d Unpublished results.
evelopments made regarding enzymatic BFCs, where both the
nodic and the cathodic bioelement are directly connected to the
lectrode. We  brieﬂy discuss the bioelements and electrode designs
sed, and then we take a closer look at the DET based BFCs reported
o far, comparing the performances and evaluating their applica-
ion as power sources in potentially implantable biodevices. We
lso present some previously unpublished data obtained with the
lucose/O2 BFC recently developed in our research group.
. Bioelements for DET based biodevices
Which bioelements to use in the construction of a BFC depends
n the fuel and oxidant one intends to exploit to extract elec-
ric power. Most BFCs for potentially implantable purposes are
esigned to utilize O2 reducing enzymes at the cathode and glu-
ose oxidizing enzymes at the anode, since the biooxidant and the
iofuel are available in different human physiological ﬂuids, such
s blood, plasma, saliva, and tears (lachrymal liquid) (Table 2).
However, it should be emphasized that in vivo the available
mounts of O2 and glucose are not as high as it is usually sug-
ested. Let us give some concrete examples. Free O2 concentration
s almost ﬁve times lower in blood and ten times lower in saliva,
ompared to air-saturated electrolytes in vitro, since most of the O2
olecules are bound to hemoglobin in the human vascular system
20] or consumed during different enzymatic reactions occurring
n the human oral cavity [21]. As for free glucose in vivo, recent
tudies showed quite low concentrations of this biofuel in saliva
22] and especially human lachrymal liquid [23], compared to old
ata available in the literature [24] (Table 2). Several reasons can be
ffered to explain the huge glucose concentration variation in vivo,
.g. biological variability, differences in collection procedures (stim-
lated or un-stimulated saliva was analyzed, basal or induced tearswere investigated, etc.), and inadequate detection limits in previ-
ously used procedures, especially, when it comes to small available
human tear volumes. Thus, the performance of similar glucose/O2
BFCs can vary signiﬁcantly in different physiological ﬂuids (vide
infra).
2.1. Cathodic redox enzymes
Blue multicopper oxidases (BMCOs), e.g. ascorbate oxidase
(AOx), laccase (Lc), bilirubin oxidase (BOx), and ceruloplasmin (Cp)
[25–27], have been investigated extensively for possible usage as
cathode bioelements. In most cases high redox potential Lcs and
BOxs have been employed to build cathodes for DET based BFCs
(Fig. 2A). An extensive review regarding DET between BMCOs  and
different types of electrode was published by Shleev et al. in 2005
[28]. Crystal structures of Zucchini AOx [29], different Lcs [30,31],
human Cp [32], and more recently Myrothecium verrucaria BOx
[33,34] have been determined (Fig. 3). The crystallographic data
have helped to signiﬁcantly increase the understanding of the
mechanism of the enzymatic processes during heterogeneous bio-
electrocatalytic reactions [28,35–37].
The catalytic site of most of BMCOs consists of four copper
atoms; the T1 site (Cu-T1) at which electrons are accepted from
substrates, and which also can be electrically coupled directly
to an electrode; the T2/T3 copper cluster (Cu-T23), where O2 is
bound and reduced to H2O. Some BMCOs have a more compli-
cated structure, e.g. human Cp contains six Cu ions, three Cu-T1
and Cu-T23 (Fig. 3). Lcs and BOxs can oxidize a wide range of
substrates, concomitantly reducing O2 to H2O by means of a “ping-
pong” mechanism, whereas other enzymes, e.g. Cp, act according
to an “ordered” mechanism. Indeed, for Cp non-turnover DET is
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Table  2
Concentration of biofuel (glucose) and biooxidant (oxygen) in human physiological ﬂuids.
Medium Glucose concentration (mM)a
[literature values (mM)]
Oxygen concentration (mM)a,b
(Literature values (mM))
Blood 4.8
(∼5, Guyton and Hall [20])
0.22
(∼0.05–0.13, Guyton and Hall [20])c
Plasma 5.6
(∼5.6, Guyton and Hall [20])
0.25
Saliva (un-stimulated) 0. 3
(∼0.08 Jurysta et al. [22])
0.25
(0.0025, Cohen et al. [21])
Tears  (basal) n.d.
(0.1–0.6, Berman [24])
(0.013–0.051, Taormina et al. [23])
n.d.
(∼0.25, Efron [106])
n.d., not determined.
a Glucose concentration was  estimated using a HemoCue glucose analyzer (HemoCue AB, Ängelholm, Sweden) and O2 concentration was estimated by an Oxygraph clark
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c O2 present in the blood is bound to hemoglobin [20].
sually observed, however, without mediatorless bioelectrocatal-
sis [37].
DET between the enzymes and different electrode materials,
uch as gold and graphite, has been achieved using different
mmobilization strategies in attempts to appropriately orient the
nzymes for efﬁcient ET [38–40].  Lcs usually exhibit the highest
ctivity in slightly acidic media, about pH 4–5, and are inhibited
n the presence of chloride ions. High potential Lcs have T1 site
edox potentials of up to 780 mV  vs. NHE [28]. BOx usually retains
 high activity at neutral pH and is less sensitive to chloride ions,
ircumstances that make BOx a suitable choice for BFCs operating
n human physiological ﬂuids. The BOx class of enzymes however,
ave slightly lower Cu-T1 redox potentials than the high redox
otential Lcs, i.e. approximately 670 mV  vs. NHE [41,42]. Cathodes
ased on BMCOs can be made quite efﬁcient, with current den-
ities in the mA  cm−2 range; the efﬁciency being limited by O2
iffusion to the electrode surface [43–45].  If H2O2 instead is uti-
ized as the biooxidant, enzymes that can reduce this compound,
.e. microperoxidase-11 (MP-11) and horseradish peroxidase (HRP),
an be used to construct DET based biocathodes [46–48].
.2. Anodic redox enzymes
When trying to design a BFC using glucose as a fuel, glucose oxi-
ase (GOx) is the obvious choice [49]. GOx carries a ﬂavin (FAD),
ith the catalytic pocket buried within the enzyme (Fig. 4A). This
omplicates the electric coupling of the enzyme to the electrode
nd hence DET is unlikely, a restriction that has foiled the attempts
ig. 2. Highly puriﬁed large-scale preparations of bioelements used for the constructio
cellobiose dehydrogenase).amount of dissolved O2 in an air-saturated solution at 25 ◦C is ∼0.25 mM)  [113].
to use this enzyme in DET based biodevices so far. It should be noted
that in many publications authors claim to have achieved DET using
different nanomaterials and native GOx, e.g. carbon nanotubes
(CNTs) and nanoparticles (NPs) [50–55],  or by using the deglyco-
sylated [56] or genetically modiﬁed enzymes [57]. However, there
is an ongoing debate whether if it truly is DET based bioelectro-
catalytic oxidation of glucose, or if the obtained current responses
are due to some other processes, e.g. naturally mediated bioelec-
trocatalytic oxidation of glucose by free FAD diffused out from the
active centers of some enzyme molecules, H2O2 mediation, etc.  The
point is that already in nineteen eighties well-pronounced Faradaic
responses on GOx-modiﬁed carbon electrodes were registered in
the absence of redox mediators [58–61]. Based on the obtained
results it was however concluded that some enzyme molecules
on the electrode surface were denatured (thus readily releasing
FAD), and the redox cofactor acted as the natural mediator in these
bioelectrocatalytic systems. Thus, despite the large number of pub-
lications concerning DET between GOx and different electrodes,
one has to be extremely careful in the interpretation of the observed
bioelectrocatalytic and non-turnover signals from GOx-modiﬁed
electrodes [62].
Another enzyme that can use glucose as a substrate is cellobiose
dehydrogenase (CDH) [63]; CDH has received increasing attention
and has now been utilized in DET based BFCs [64–66].  CDH con-
sists of both a FAD domain and a heme c domain (Fig. 4C), where
the FAD is responsible for substrate oxidation and the heme facili-
tates the electric coupling to the electrode material [67]. A problem,
when using CDH as an anode bioelement to oxidize glucose, is that
n of biofuel cells. A – cathodic redox enzyme (laccase); B – anodic redox enzyme
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apiens  ceruloplasmin (PDB 1KCW); D – Cucurbita pepo var. melopepo (zucchini) asc
lucose is not the target substrate of the enzyme; hence the cat-
lytic efﬁciency is not as high as for GOx. The native substrate of
DH is obviously cellobiose, but the enzyme is also able to oxidize
actose with high efﬁciency.
Fructose is another carbohydrate fuel in BFC applications. Immo-
ilization of fructose dehydrogenase (FDH), carrying one FAD and
ne heme c domain (similar to CDH), on electrodes is known to
rovide DET mode cells [68,69].
Apart from being based on different carbohydrate fuels, other
ET BFCs rely on alcohols, employing immobilized alcohol dehy-
rogenase (ADH) (Fig. 4B) [70,71], or H2, using hydrogenase (Hd)
Fig. 4C) [19].
.3. General aspect of enzyme based bioelectrocatalysis
Enzymes in general are excellent catalysts with distinct sub-
trate speciﬁcity and high efﬁciency, regularly reaching catalytic
urnover numbers of up to 1000 s−1. Enzymes are however rather
arge molecules so the actual mole fraction efﬁciency is not as high
s in non-biogenous catalysis. This is very important when trying to
esign BFCs generating high current densities, e.g. in the mA cm−2
ange. Hence, Barton et al. made theoretical calculations based on
 100 nm2 enzyme with a kcat of 500 s−1, placing the theoretical
imit at about 80 A cm−2 [8].  When current densities in the order
f mA  cm−2 are desired, several (mono)layers of enzyme would
ave to be immobilized, with efﬁcient electric coupling to the elec-
rode [72–75].  The utilization of nanostructures when designinge (PDB 1GYC); B – Myrothecium verrucaria bilirubin oxidase (PDB 2XLL); C – Homo
 oxidase (PDB 1AOZ).
electrodes, to create expanded three-dimensional assemblies is
therefore very important.
Limited long-term stability of BFCs is another problem, which
is caused by the inherent short active lifetimes of many enzymes.
Enzymes in solution often have lifetimes in the order of hours up
to days. By immobilizing enzymes on electrodes via physisorption,
entrapment, chemical bonding, or cross-linking, the lifetime can be
signiﬁcantly increased, up to months [5].  This is quite short if the
intended application of the BFC is as part of an implantable device
operating in the human body, which preferably would require
year-long stability. Active lifetimes have however been extended
beyond one year through encapsulation of the enzyme in differ-
ently designed micelles, which physically conﬁnes the enzyme and
prevents denaturation [76,77].
3. Electrode materials
Either bare (unmodiﬁed) or modiﬁed electrodes fabricated from
different materials are used to create “enzyme electrodes”  suit-
able for BFC applications. Moreover, many different strategies have
been developed to immobilize enzymes on electrodes with nanos-
tructured features, such as mesoporous materials, NPs, nanoﬁbers,
nanotubes (NTs), and nanocomposites [78]. A larger surface area
enables a higher enzyme loading and can also improve the stabil-
ity of the immobilized enzyme; a high enzyme load is critical to
obtain high-performance enzymatic BFCs, vide supra. As an added
beneﬁt, co-immobilization of the enzyme and nanostructures can
sometimes also facilitate DET.
196 M. Falk et al. / Electrochimica Acta 82 (2012) 191– 202
Fig. 4. The crystal structures of different anodic redox enzymes. A – Aspergillus niger glucose oxidase (PDB 1CF3), B – Pseudomonas putida alcohol dehydrogenase (PDB 1KV9),
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s–Desulfovibrio gigas hydrogenase (PDB 2FRV), D–Phanerochaete chrysosporium cel
nknown, the current structure was rendered using the cytochrome and the FAD d
So far only a limited number of materials have been used
o design DET based BFCs. Spectrographic graphite is a conve-
ient electrode material to use: it is easy to work with, very
heap, and naturally highly porous, enabling higher enzyme load-
ngs [79,80]. Indeed, the very ﬁrst glucose/O2 mediator-, cofactor-,
nd membrane-less BFCs were created by enzyme physisorption
n spectrographic graphite electrodes (SPGE) [64,65]. Modifying
lectrodes with metal or carbon NPs, such as Au NPs or Ket-
en black (KB), respectively, permits the formation of electrodes
ith very high roughness factors and consequently, successful
esign of efﬁcient biodevices. Several examples of DET based
FCs with usage of Au NPs and KB can be found in the litera-
ure [66,81].  CNT based materials have received a lot of attention
ately, exhibiting many important features for enzyme immobiliza-
ion [82]. Being either single-walled (SW) or multi-walled (MW),
NTs typically have diameters ranging from a few to several tens
f nanometers, with lengths of up to hundreds of micrometers,
nd have been used in DET based BFCs to facilitate electron trans-
er between the electrode and GOx [83–85].  The usage of CNTs in
ioelectronics [86], including BFC fabrication has been reviewed
ecently [87,88],  where integration of CNTs with biological mate-
ial provided hybrid materials useful in nanoscale BFCs and even
elf-powered nanobiodevices [83,89].e dehydrogenase. Since the complete structure of cellobiose dehydrogenase is still
s of the enzyme (PDB 1D7D and PDB 1NAA, respectively).
Further progress in nanostructured materials will be necessary
for the development of high-power and stable DET based enzy-
matic BFCs. One thing to take note of is the per se effects the chosen
support material used in electrode design may  have. When consid-
ering glucose, several auxiliary supports, e.g. Au and Si NPs, have
shown activity towards glucose electrooxidation [90,91]. If CNTs
are used without meticulous puriﬁcation, contamination from the
transition metals catalysts used in the CNT fabrication is unavoid-
able [92]; impurities such as iron oxide and copper oxide have been
shown to catalyze glucose oxidation [93,94].
4. Comparison of the reported DET based biofuel cells
A short summary of the design and performance of DET based
BFCs operating at different conditions, reported in the literature
so far, is presented in Table 1. A direct performance comparison
is however less than straightforward since: (i) different opera-
tional conditions were used (stirring, substrate concentration, etc.),
(ii) different assessment protocols regarding characterization, per-
formance, etc. were employed. With regard to the stability of a
particular BFC, one thing to take note of is that stability results
might be interpreted as adequate when in fact the enzyme is con-
tinuously denatured or desorbed from the electrode surface. This
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an happen when the power generated by the BFC is limited by
ubstrate mass transport, and not by the amount of active enzyme.
As was mentioned above the very ﬁrst BFC where both the
nodic and the cathodic bioelements were in DET contact with elec-
rodes, was reported in 2002 by Tarasevich et al. [19]. In terms
f design, the anodic and cathodic compartments of the H2/O2
iodevice were separated, with different catholyte and anolyte pH
alues, 4.2 and 8.0, respectively, resulting in an extraordinary high
pen circuit voltage (OCV) of 1.35 V. Three years later a mediator-,
ofactor-, and membrane-less H2/O2 BFC was reported by Arm-
trong’s group [95]. They created the biodevice using Hd and Lc
dsorbed on graphite electrodes and no membrane was used in
he BFC construction. Moreover, the Hd-modiﬁed anode was  com-
letely unaffected by CO and only partially inhibited by O2 because
f the proper choice of the bioelement and construction of the
nzyme electrode. On running, an OCV of 0.97 V with a maximum
ower density of 7 W cm−2 was registered in a pH 5 citrate buffer
ith air and H2 inlets in close proximity to the cathode and anode,
espectively. The BFC generated stable currents for over 15 min
Table 1).
The very ﬁrst and, to our best knowledge the only report on an
thanol (EtOH)/H2O2 enzymatic FC, where both bioelements were
n DET contact with the electrodes, was published in the beginning
f 2005 by Ramanavicius and co-workers [71, #60] (Table 1). More-
ver, this work can be considered as the ﬁrst report on a membrane-
nd mediator-less, cofactor-free BFC. The redox enzymes, i.e.  alco-
ol dehydrogenase (ADH; for the bioanode), and a microperoxidase
MP-11)/GOx combination (for the biocathode) were chemisorbed
y means of glutaraldehyde (GA) crosslinking on carbon rod elec-
rodes. MP-11 was in DET contact with the electrode, reducing the
2O2 produced by GOx when glucose was present in the solution,
hereas ADH oxidized EtOH to acetaldehyde at the anode. The BFC
as able to generate 0.18 W cm−2 at 0.1 V and showed an OCV
f 0.27 V in acetate buffer, pH 6, with 10 mM of H2O2 and EtOH
dded to the solution. The BFC had an operational half-life of 2.5
ays (Table 1).
Two different reports have been published on DET-based BFCs
tilizing fructose [81,84]. In the ﬁrst, Kano and co-workers con-
tructed a one-compartment BFC by adsorbing FDH on a KB particle
odiﬁed carbon anode and Lc on a carbon aerogel cathode (Table 1).
he BFC had an OCV of 0.79 V and power densities reaching
50 W cm−2 at 0.41 V, in an O2 saturated McIlvaine buffer, pH 5.0
ontaining 200 mM of fructose, under stirring. The BFC was reason-
bly stable with a half-life of over 12 h. Mass transfer of O2 limited
he cathode, and when measurements were performed without
onvection, the power dropped to 390 W cm−2. Slade and col-
eagues later reported on a FDH/BOx based BFC, where the enzymes
ere adsorbed on MWCNT-modiﬁed glassy carbon electrodes [84].
he BFC stability was greatly improved, with a half-life of about
7 h, although the power density was relatively low, 126 W cm−2erum, plasma; B – saliva; C – lachrymal liquid (tears).
at 0.35 V with an OCV of 0.66 V (Table 1). However, the measure-
ments were done in air-saturated solutions without convection,
and when large currents were drawn, mass transfer of O2 limited
the power.
Roughly half of the DET based BFCs reported to date are designed
to utilize glucose as the biofuel and O2 as biooxidant (Table 1).
Since glucose is readily available in human physiological ﬂuids
(e.g. blood, saliva, and tears) the utilization of enzymatic FCs in
potentially implantable, i.e. both in vivo and extra vivo (or ex vivo)
situations, can be envisioned. Here, for the ﬁrst time, we would like
to introduce the term “ex vivo” (substituting the previously used
illogical “semi-implantable”) regarding attachable, adhesive, ﬂoat-
ing devices operating in saliva, tears, and sweat, which somehow
lies in between in vivo and in vitro situations.
Shleev et al. reported on the ﬁrst DET based BFC utilizing glu-
cose as biofuel and O2 as biooxidant. Indeed, that work was chosen
as a cover page of PCCP [65]. CDH and Lc were adsorbed on SPGE
and the BFC showed an OCV of 0.73 V and was able to generate
over 5 W cm−2 at 0.5 V in a citrate buffer pH 4.5 containing 5 mM
glucose (Table 1). The power output increased insigniﬁcantly with
stirring of the solution and the biodevice was able to deliver power
with about 10% drop in efﬁciency only, after 5 h of continuous oper-
ation.
The same group later utilized a similar CDH based anode
together with a BOx modiﬁed cathode [64]. Different bioelements,
i.e. BOx instead of Lc and CDH from ascomycete instead of basid-
iomycete, were used to design a biodevice, which operates at
physiological pH in the presence of chloride ions, generating a
power density of around 3 W cm−2 at a cell voltage of 0.37 V and
an OCV of 0.62 V, when investigated in 5 mM glucose, PBS pH 7.4.
Because the BFC was functional at neutral pH in the presence of
0.15 M NaCl it was  also tested in human serum. For this purpose
human blood was collected from a healthy volunteer and serum
was prepared as known in the arts (Fig. 5A). In serum, the power
maximum was similar to that in buffer, with an OCV of 0.58 V. How-
ever, a second maximum, 4 W cm−2 at 0.19 V, appeared in the
power density plot. This peak was attributed to the oxidation of
some redox active species, apart from glucose, present in serum,
e.g. ascorbic acid or urate [64]. The stability of the BFC was not
so high, with a half-life of only 6 h and 1.5 h in buffer and serum,
respectively (Table 1).
A couple of DET based BFCs utilizing GOx  have emerged in the
recent years. Pan with co-workers was the ﬁrst group reporting on
a proton-conductive nanowire based BFC [83]. Lc was  immobilized
on the cathode and GOx together with CNTs were used to create
the anode. The observed currents from the anode were attributed to
DET based bioelectrooxidation of glucose. The BFC was investigated
in 55 mM glucose PBS pH 7, and in human blood. The OCV  was only
0.23 V in neutral buffer but the BFC had a maximum power density
of ∼30 W cm−2. In blood the OCV was reduced to 0.12 V with a
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aximum power density of about 5.6 W cm−2 (Table 1). Cosnier’s
esearch group later reported on a GOx/Lc based BFC with very
mpressive characteristics [85]. Electrodes were created by com-
ressing high amounts of protein with MWCNTs using a hydraulic
ress. In this way disk electrodes either containing GOx, with added
atalase to prevent accumulation of deleterious amounts of H2O2
bioanode), or Lc (biocathode), were prepared. Finally both disks
ere covered with a cellulose ﬁlm. When the BFC was operated in
0 mM glucose PBS pH 7, an OCV of about 0.95 V with a maximum
ower density of 1.3 mW cm−2 at 0.6 V was registered (Table 1). The
FC was capable of delivering 200 A cm−2 for 2 h, with a voltage
rop of 0.95–0.6 V during the time of operation. As of this date, these
re by far the most impressive characteristics obtained for any DET
ased enzymatic FC (cf. basic parameters of glucose/O2 biodevices
n Table 1). However, the detailed mechanism of operation of native
non-glycosylated) GOx in DET mode, as well as the bioelectrocat-
lytic reactions of the high redox potential Trametes versicolor Lc at
eutral pH in the presence of a signiﬁcant concentration of chloride
ons, remain unclear.
We  recently reported on a Au NPs based BFC, with enhanced
erformance compared to the previously reported SPGE-based BFC
66]. The BFC was constructed using macroscale Au electrodes from
BAS” (Bioanalytical Systems, West Lafayette, IN, USA; Ø = 3 mm)
odiﬁed with Au NPs (Ø ca. 15 nm)  (Fig. 6A), where the anode
as created by crosslinking the CDH with glutaraldehyde on top
f thiol modiﬁed Au electrodes and the cathode was prepared by
imple adsorption of BOx. The performance of the biodevice was
valuated in both 5 mM glucose PBS pH 7.4 and in human physi-
logical ﬂuids, e.g. blood and plasma (Table 1), using a macroscale
lass electrochemical cell with a total volume of 10 mL  (Fig. 7A, left bioanodes. A – macroscale electrode; B – microscale electrode.
part). When operated in buffer, the cell had an OCV of 0.66 V with a
maximum power density of 3.3 W cm−2 at a cell voltage of 0.52 V;
the performance was only slightly reduced in the physiological ﬂu-
ids (Fig. 8). The BFC had a half-life of 30 h, when operated in glucose
containing buffer; the half-life was  reduced to about 8 h and 2 h in
plasma and blood, respectively (Fig. 9).
5. DET based glucose/oxygen biofuel cells for ex vivo
applications
One should clearly understand that the reported in vivo per-
formances of BFCs already tested are untenable [96]; based not
only on the intrinsic properties of BFCs, i.e. operating voltage,
power density, and operational stability, which per se can be signif-
icantly improved using bionanotechnological approaches [85], but
also on very serious complications developing as a consequence of
implantation, i.e. immunoresponse, incapsulation, etc. One promis-
ing biomedical application of BFCs, which has not been realized yet,
is the employment of these devices in non-invasive (ex vivo) contact
situations, where most of the in vivo shortcomings are non-issues.
Taking this into account we have recently investigated the function
of a DET based glucose/O2 BFC in different ex vivo situations.
5.1. Operation of macroscale Au NPs based BFC in human saliva
Human resting saliva was  collected from a healthy volunteer as
known in the arts (Fig. 5B) and the BFC operation in this physiolog-
ical ﬂuid was investigated (Table 1); the previously unpublished
results are presented in Figs. 8 and 9. When operated in saliva the
CDH/BOx/Au NPs based biodevice displayed an OCV similar to that
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sed  for the construction of three-dimensional bioanodes and biocathodes.
n blood, but had a maximum power density of 2.1 W cm−2 at an
perational voltage of only 0.16 V, a much lower cell voltage than
hen operated in glucose-containing neutral buffers and blood
Fig. 8). The poor performance of the BFC can be easily explained by
he much lower glucose concentration present in saliva compared
o blood, i.e.  as low as about 100 M (cf. glucose concentrations in
ig. 8. Typical dependencies of the power density on the operating voltage of Au
Ps based glucose/O2 biofuel cells in air-saturated quiescent solutions: (a) in PBS
H 7.4 containing 5 mM glucose; (b) in human blood; (c) in human plasma; (d) in
n-stimulated human saliva; (e) in human basal tears.cale to a microscale deivce; B – SEM images of an Au NPs modiﬁed Au microwire
Table 2) [22,97].  The peak at 0.16 V corresponds, in all likelihood,
to some other compounds being oxidized at the anode and that
are present in different human physiological ﬂuids including saliva
(vide infra). In regard to the stability of the BFC in saliva, an almost
70% drop of power density was observed after continuous operation
for 10 h (Table 1). The power density loss was mostly due to a large
Fig. 9. Variation of the power output for Au NPs based glucose/O2 biofuel cells with
time in air-saturated and quiescent media: (a) in PBS pH 7.4 containing 5 mM glu-
cose; (b) in human blood; (c) in human plasma; (d) in human resting saliva; (e) in
human basal tears.
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Fig. 10. “Smart” electronic contact lenses. A – image of a tentative device in a human eye; B – fabricated single-pixel wireless display based on a contact lens in vivo tested
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dapted from Lingley et al. [104], with some additions and changes.
nitial drop, possibly because of the adsorption of some
iomolecules on the electrode surface, e.g. mucins, after which
he generated power was quite stable (Fig. 9d). To clearly under-
tand the performance of glucose/O2 BFC in human saliva additional
nvestigations are obviously needed.
.2. Operation of a microscale Au NPs based BFC in human tears
Among many devices operating in ex vivo modes, e.g. skin and
ral electronic patches [98], as well as electronic contact lenses
104], one can easily identify exciting devices with huge future
pplication potentials for e.g. human supervision. Many compelling
ictures and even movies regarding this spectacular topic are avail-
ble from non-scientiﬁc sources nowadays, e.g. Fig. 10A. However,
abrication and even in vivo tests of wireless contact lens displays
ave been already initiated (Fig. 10B). Another intriguing applica-
ion for “smart” contact lenses is non-invasive biomedical sensing.
uch sensing devices have already been realized to measure eye
ovement [99], corneal temperature [100], glucose concentrations
101], and were even tested in vivo showing adequate correla-
ion between blood and tear glucose levels in rabbits [102]. Since
smart” contact lenses ideally should work wirelessly, identifying
n appropriate power source for such devices is a major challenge.
ontemporary batteries are not really applicable due to the speciﬁc
equirements for human contact lenses, i.e.  the available volume
s limited considering the surface area, about 1 cm2, and a thick-
ess of 0.2 mm or smaller [103]. Consequently, an antenna, a silicon
ased power harvesting device (Fig. 10B), was used in the very ﬁrst
irelessly powered contact lens display [104].
We believe that a DET based BFC would be an outstandingly
etter approach to design self-powered “smart” contact lenses
ompared to antennas, which rely on electromagnetic radiation.
ndeed, we pioneered investigation of a Au NPs based glucose/O2
FC in human lachrymal liquid (tears) [105]. For this purpose
uman basal tears were collected from a healthy volunteer using
lass capillaries, as known in the arts (Fig. 5C), and BFC operation
n this physiological ﬂuid was investigated (Table 1). Since the total
olume of basal tears is less than 10 L, a microscale glucose/O2 BFC
as built and tested in a microcell consisting of a glass capillary
ith a total volume of ca. 10 L (Fig. 7A, right part). The biode-
ice was designed using Au microwires (Ø = 100 m)  modiﬁed with
u NPs and redox enzymes as schematically illustrated in Fig. 6B.
he three-dimensional structure of the NP modiﬁed Au microwire
ased biocathodes and bioanodes were conﬁrmed by AFM (data not
hown) and SEM (Fig. 7B).
When operated in tears, the CDH/BOx/Au NPs based biodevice
howed an OCV of 0.57 V, but the maximum power density of
.5 W cm−2 was realized at an operational voltage of only 0.2 V,a much lower cell voltage compared to blood and glucose contain-
ing neutral buffers (Fig. 7). Additional studies conﬁrmed that the
peak at 0.2 V corresponded to some other compounds being oxi-
dized at the anode, compounds present in tears at very signiﬁcant
concentrations, e.g. ascorbic acid and dopamine. At 0.5 V, a crucial
minimal voltage to power modern semiconductor based transis-
tors, and hence, to allow the design of useful electronic devices,
the BFC had a power density of only 0.8 W cm−2. The poor per-
formance of the BFC can be easily explained by the much lower
glucose concentration in tears compared to blood [23], which can
be as low as 13 M (cf. glucose concentrations in Table 2). Con-
trary to the biofuel concentration, the concentration of biooxidant
in lachrymal liquid is very high since human tears are O2 saturated
during waking hours [106]. With regard to the stability of the BFC
in tears, a 25% drop of power density was  observed after continu-
ous operation of the biodevice for 12 h (Fig. 8). Detailed information
concerning the fabrication of microscale Au NPs based glucose/O2
BFC and its performance in human lachrymal liquid can be found
in our recently published work [105].
6. Conclusions and further perspectives
It is obvious that at least at the current stage of development,
enzymatic FCs cannot compete with conventional FCs in terms of
raw power output and stability. However, several niches of possi-
ble applications for BFCs can be envisioned, where said regular FCs
would not be suitable or would not work at all.
One attractive application would be as portable power sources
that could be easily recharged, e.g. by just refueling with a sugar
containing solution. This could be used to power portable elec-
tronic devices in situations where there is no other easy way  to
power and charge the device. Akerman Inc. (www.akkerman.com),
an established company that is trying to commercialize BFCs, has
demonstrated prototypes such as an EtOH/air BFC stack that could
power an iPod [107]. Recently, Sony Corporation developed a multi-
stacked BFC running on a sugar containing solution that was able to
generate over 1.25 mW mL−1, which is enough power to be used in
many applications, and was shown to successfully power a remote
controlled car [108].
Another possible application for enzymatic FCs in general, and
glucose/O2 BFCs in particular, is usage as implantable electrical
power sources [8,9]. A very appealing idea is to create a stable
BFC able to generate enough power from glucose and O2 available
in human blood (Table 2) to power different sensors, pacemak-
ers, or other devices. To use a BFC operating in blood for a long
time without protecting the electrodes with a suitable membrane
would however be very difﬁcult. Accordingly, membrane-less DET
based biodevice designs most likely are futile. Also, a successful
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mplantation would have to deal with possible inﬂammation and
ctivation of the immune system, thrombosis, and ﬁnally operate
fter ﬁbrous encapsulation of the implant as healing occurs [109].
 BFC that would power e.g. a pacemaker, would have to be very
obust in terms of reliability, efﬁciency, and stability, for it to ever
e utilized as power source.
Other human physiological ﬂuids, like saliva and tears, can be
ess corrosive than blood, with the added beneﬁt of being available
ithout requiring surgery [24,97].  Thus, the merits of a BFC work-
ng in non-invasive, i.e. in ex vivo situations, e.g. on a tooth in the
outh, on different parts of skin, or on a contact lens in the eye,
an easily be estimated. Saliva has been suggested for non-invasive
onitoring applications, where sensing devices could be inserted
r implanted in the oral cavity [110,111].  Recently, glucose sensors
mbedded in contact lenses for non-invasive monitoring of glucose
ave been demonstrated [101,102].  However, before any authentic
mplementation of implantable BFCs can be realized, considerable
mprovements need to be made, increasing the power output as
ell as the stability of enzymatic FCs. Thus driven, the ﬁeld is
onstantly developing with new and more suitable nanostructures
eing designed and in parallel, genetically engineered enzymes,
apable of higher catalytic turnover numbers, with lower KM-
alues, and with more efﬁcient ET, are becoming available. Cascades
f different redox enzymes can be used to improve the coulombic
fﬁciency and fuel ﬂexibility of BFCs [6,112] taking advantage of low
mounts of a spectrum of available biofuels. For biodevices work-
ng in saliva and especially tears, where both concentration and
otal amount of glucose are a priori very low (Table 2), but other
uels are present, e.g. ascorbate and dopamine, a cascade based BFC
ould perhaps be perfectly suited. Moreover, multicatalytic BFCs,
.e. biodevices based on rational co-immobilization of inorganic,
rganic, and biological catalysts, can be also used in these extreme
ituations. Thus, fabrication and characterization of efﬁcient and
table multicatalytic glucose-ascorbate-dopamine/O2 BFCs operat-
ng in human lachrymal liquid is currently under development in
ur laboratory.
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